Flputnam Investment Management Co. Has $32.81 Million Stake in Boston Scientific Corporation $BSX

Flputnam Investment Management Co. raised its holdings in Boston Scientific Corporation (NYSE:BSX) by 237.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 336,059 shares of the medical equipment provider’s stock after buying an additional 236,586 shares during the period. Flputnam Investment Management Co.’s holdings in Boston Scientific were worth $32,809,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Steph & Co. bought a new position in shares of Boston Scientific in the 3rd quarter valued at about $25,000. 1248 Management LLC bought a new stake in Boston Scientific during the first quarter worth about $26,000. FWL Investment Management LLC bought a new stake in Boston Scientific during the second quarter worth about $26,000. Sound Income Strategies LLC boosted its position in Boston Scientific by 90.9% during the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 120 shares during the last quarter. Finally, Kilter Group LLC bought a new position in Boston Scientific in the second quarter valued at approximately $30,000. 89.07% of the stock is owned by institutional investors.

Insider Buying and Selling at Boston Scientific

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total value of $4,973,500.00. Following the transaction, the executive vice president owned 178,342 shares of the company’s stock, valued at approximately $17,739,678.74. This represents a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the sale, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. The trade was a 42.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 143,095 shares of company stock valued at $14,228,950 in the last three months. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Trading Down 0.5%

Shares of Boston Scientific stock opened at $95.61 on Friday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96. The business has a fifty day simple moving average of $98.64 and a two-hundred day simple moving average of $101.26. Boston Scientific Corporation has a 1 year low of $85.98 and a 1 year high of $109.50. The company has a market capitalization of $141.74 billion, a price-to-earnings ratio of 51.13, a P/E/G ratio of 1.93 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.71 by $0.04. The firm had revenue of $5.07 billion for the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The company’s quarterly revenue was up 20.3% on a year-over-year basis. During the same period in the previous year, the company earned $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. Wells Fargo & Company upped their price objective on Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a research note on Thursday, October 23rd. Truist Financial lowered their target price on shares of Boston Scientific from $130.00 to $120.00 and set a “buy” rating on the stock in a report on Thursday. Barclays upped their price target on shares of Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a research report on Thursday, October 2nd. Oppenheimer upgraded shares of Boston Scientific from a “market perform” rating to an “outperform” rating and increased their price target for the company from $118.00 to $125.00 in a research note on Monday, September 8th. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of Boston Scientific in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $124.85.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: RBC Capital continues to rate BSX as an “outperform,” reinforcing buy-side support from a major bank and likely helping demand for shares. RBC Capital maintains Boston Scientific (BSX) outperform recommendation
• Positive Sentiment: Royal Bank of Canada analyst commentary suggests upside ahead for BSX, adding another institutional voice expecting price appreciation. This supports the bullish narrative among analysts. Boston Scientific (NYSE:BSX) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says
• Positive Sentiment: Truist reaffirmed a “buy” rating on BSX, signaling continued analyst confidence even as the firm updated its outlook—this helps underwrite medium-term investor sentiment. Truist Securities maintains Boston Scientific (BSX) buy recommendation
• Positive Sentiment: Zacks highlights BSX’s global expansion push — R&D, AI-driven manufacturing and a focused Emerging Markets effort targeting $1B+ revenue in China for 2025 — a strategic growth catalyst that supports longer-term upside. Boston Scientific’s Global Expansion: What’s Behind the Growth?
• Neutral Sentiment: Options flow is active around BSX; Benzinga’s options-focused piece notes positioning that can amplify intraday moves but doesn’t definitively indicate directional conviction from fundamental investors. Watch open interest and strike concentration for short-term signals. Decoding Boston Scientific’s Options Activity: What’s the Big Picture?
• Neutral Sentiment: Informational pieces recap BSX’s multi-year performance; useful for context but unlikely to move the stock today. These highlight solid historical returns that underpin investor confidence. Here’s How Much You Would Have Made Owning Boston Scientific Stock In The Last 5 Years
• Neutral Sentiment: Short-term market commentary notes BSX outperformed earlier sessions; useful for momentum traders but not a standalone fundamental driver. Boston Scientific (BSX) Advances While Market Declines
• Negative Sentiment: Truist cut its price target from $130 to $120 — a downward revision that may cap near-term upside and pressures sentiment despite the maintained “buy” rating. That target trim likely explains some of the selling pressure today. BSX price target lowered by Truist

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.